Tricida picks up $55 mln Series C

South San Francisco-based Tricida, a biopharmaceutical company focused on chronic kidney disease, has raised $55 million in Series C funding. Longitude Capital led the round with participation from Vivo Capital, OrbiMed, Sibling Capital Ventures and Limulus Venture Partners. In conjunction with the funding, Dr. David Hirsch, a managing director at Longitude, has been added to Tricida’s board.

Source: Press Release